Metastatic Osteosarcoma Treatment Market, By Drug (Doxorubicin, Dactinomycin, Denosumab, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2018-2026

  • To Be Published : Aug 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Osteosarcoma or bone cancer is a type of cancer were bone tissues show an abnormal growth. Osteosarcoma that spreads from initially affected area to distant site is known as metastatic osteosarcoma. Metastatic osteosarcoma often spreads to lungs, whereas less commonly spreads to other bones, brain or other organs. Symptoms of metastatic osteosarcoma varies based on the location of tumor, for example bone pain, bone fracture, swelling, redness, limping, and limited joint movement. If the tumor spreads to the lungs the symptoms include chest pain, shortness of breath, cough with blood, chronic coughing or wheezing. Diagnostic tests for metastatic osteosarcoma includes CT-scan, MRI, X-ray, PET scan, biopsy, and bone scan. Treatment of metastatic osteosarcoma involves surgery, radiation, chemotherapy, biological therapy or a combination of these treatments. Combinational treatment also known as multi-modality treatment is more preferred by medical practitioners to increase treatment outcomes or to prolong survival.

Metastatic Osteosarcoma Treatment Market – Drivers

Increasing drug pipeline for malignant bones and soft tissue (Ewing Sarcoma) cancer is expected to drive growth of metastatic osteosarcoma treatment market. For instance, in 2017, Merck & Co., Inc., studies the effects of Pembrolizumab (MK-3475) in patients with relapsed or metastatic osteosarcoma and reported that these patient are not eligible for curative surgery. Currently, study is in phase II clinical trial and is expected to be marketed in 2023. Moreover, Novartis entered into phase II clinical trials for pazopanib for treatment of metastatic osteosarcoma as of March 2018.

Emerging new therapies for metastatic osteosarcoma treatment will further propel growth of the market. For instance, clinical trials for immunotherapy-based drugs and targeted drug therapy is expected to be a preferred option in the near future, owing to less side-effects. The immune therapy drug called immune checkpoint inhibitors can recognize and attack cancer cells exhibiting better outcomes for other cancer types and also studies have showed it is also effective for osteosarcoma treatment. Moreover, engineered monoclonal antibodies are used to stop cancer growth by hampering new blood vessel formation or to inhibit tumor cells by targeting mTOR protein. For instance, Aadi, LLC studies Nivolumab (Opdivo) in combination with ABI-009 (Nab-rapamycin, the mTOR inhibitor) for potential anti-tumor activity for Ewing Sarcoma. The study is in phase II clinical trial, which is expected to complete by 2020.

In case of pediatric osteosarcoma, around 35% of patient fail first-line of therapy, leading to recurrence in metastatic osteosarcoma in lungs. Therefore, development of novel drugs for treatment of lung cancer, due to metastatic osteosarcoma will also contribute to growth of the metastatic osteosarcoma treatment market. For instance, in 2013, Elesion Pharmaceuticals LLC, a pharmaceutical company developing life-saving therapeutics for rare cancers, entered into phase II clinical trials for Inhaled Lipid-complexed Cisplatin (ILC), a novel sustained release formulation of cisplatin in a nanoscale lipid based complex, for pediatric patients with osteosarcoma metastases for lungs. Additionally, inorganic marketing strategies adopted by metastatic osteosarcoma drug market players is expected to aid in the market growth. For instance, in the same year, Inhaled Lipid-complexed Cisplatin orphan drug designation by European Medicines Agency for the treatment of osteosarcoma. Furthermore, in 2015, company entered in partnership with Intelgen Limited, a Hong Kong-based biopharmaceutical company, for specialized novel anti-cancer drug development and commercializing ILC in Chinese market. Moreover, in 2014, Oncolytics Biotech, examined safety and efficacy of Reolysin for the treatment of bone and soft tissue sarcoma metastatic for lungs.

Metastatic Osteosarcoma Treatment Market – Restrain

Growth of the metastatic osteosarcoma treatment market can be hindered by availability of alternative therapies such as new forms of radiation therapy (intensity-modulated radiation therapy, stereotactic radiosurgery or conformal proton beam therapy). Moreover, stringent approval policies for varies drug therapies is also expected to adversely affect growth of the market.

Metastatic Osteosarcoma Treatment Market - Regional Analysis

Based on geography, the metastatic osteosarcoma treatment market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the global metastatic osteosarcoma treatment market over the forecast period, owing to increasing research and developmental activities and increasing pipeline products by market players such as Novartis and Merck & Co. Inc. Moreover, high osteosarcoma incidence contribute to the share. For instance, in 2016, American Society of Clinical Oncology (ASCO), estimated 1,000 people to be diagnosed with osteosarcoma each year. However, Asia Pacific is expected to witness fast growth in metastatic osteosarcoma treatment market, due to increasing incidence of osteosarcoma in the region.

Metastatic Osteosarcoma Treatment Market – Competitor

Key players operating in the metastatic osteosarcoma treatment market are Mylan Laboratories Limited, Actavis Inc., Alvogen Inc., Gland Pharma Limited, Sagent Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., and Luitpold Pharmaceuticals Inc.

Metastatic Osteosarcoma Treatment Market - Taxonomy

By Drug Type

  • Doxorubicin
  • Dactinomycin
  • Denosumab
  • Ifosfamide
  • Cyclophosphamide
  • Carboplatin
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.